文献速递妇科肿瘤泌尿男性生殖肿瘤

卵巢癌或前列腺癌患者树突状细胞亚群的定量与定性损伤

Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
PubMed 文献 · Eur J Cancer · 2020-06-23

研究采用流式细胞术评估卵巢癌或前列腺癌患者及健康供者全血中树突状细胞亚群的表型与功能。两组患者CD141+ DC频率均低于健康供者,但cDC1亚群仅在卵巢癌患者中减少。CD141+ DC对TLR3激动剂poly(I:C)反应降低,cDC1频率与CA125呈负相关,卵巢癌组织中CLEC9A高表达提示总生存更好。

要点

  • 卵巢癌和前列腺癌患者CD141+ DC频率均低于健康供者。
  • cDC1亚群仅在卵巢癌患者中减少,且与CA125负相关。
  • CD141+ DC对poly(I:C)反应降低提示功能受损。

核心结论

  • 卵巢癌患者cDC1减少,卵巢癌或前列腺癌患者CD141+ DC存在定量和定性损伤。
  • CD141+ DC活化可能预测功能损伤,cDC1丢失可能是卵巢癌不良预后因素。

研究设计与样本

  • 研究纳入卵巢癌或前列腺癌患者及健康供者,采用全血样本通过流式细胞术对DC亚群进行表型和功能表征。

主要发现

  • 两组患者总CD141+ DC频率均低于健康供者,但cDC1亚群仅在卵巢癌患者中减少。
  • 两组患者CD141+ DC对TLR3激动剂poly(I:C)反应均降低。
  • cDC1频率与卵巢癌肿瘤负荷标志物CA125呈负相关。
  • 卵巢癌组织中CLEC9A高表达(癌症基因组图谱数据集)提示总生存更好。

临床怎么用

  • CD141+ DC活化状态可用于评估卵巢癌或前列腺癌患者DC功能损伤。
  • cDC1频率及CLEC9A表达可能作为卵巢癌预后参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dendritic cells (DCs) are the most efficient antigen-presenting cells, hence initiating a potent and cancer-specific immune response. This ability (mainly using monocyte-derived DCs) has been exploited in vaccination strategies for decades with limited clinical efficacy. Another alternative would be the use of conventional DCs (cDCs) of which at least three subsets circulate in human blood: cDC1s (CD141bright), cDC2s (CD1c+) and plasmacytoid DCs. Despite their paucity, technical advances may allow for their selection and clinical use. However, many assumptions concerning the DC subset biology depend on observations from mouse models, hindering their translational potential. In this study, we characterise human DCs in patients with ovarian cancer (OvC) or prostate cancer (PrC). PATIENTS AND METHODS: Whole blood samples from patients with OvC or PrC and healthy donors (HDs) were evaluated by flow cytometry for the phenotypic and functional characterisation of DC subsets. RESULTS: In both patient groups, the frequency of total CD141+ DCs was lower than that in HDs, but the cDC1 subset was only reduced in patients with OvC. CD141+ DCs showed a reduced response to the TLR3 agonist poly (I:C) in both groups of patients. An inverse correlation between the frequency of cDC1s and CA125, the OvC tumour burden marker, was observed. Consistently, high expression of CLEC9A in OvC tissue (The Cancer Genome Atlas data set) indicated a better overall survival. CONCLUSIONS: cDC1s are reduced in patients with OvC, and CD141+ DCs are quantitatively and qualitatively impaired in patients with OvC or PrC. CD141+ DC activation may predict functional impairment. The loss of cDC1s may be a bad prognostic factor for patients with OvC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mastelic-Gavillet B, Sarivalasis A, Lozano LE, et al. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. Eur J Cancer. 2020. PMID: 32590296. doi:10.1016/j.ejca.2020.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。